PeptoSfera
Subscribe →

PeptoSfera

The closed sphere of peptides, biohacking, and transformation protocols.

A sphere of molecules.

Every Thursday, one is decoded — mechanism, evidence, regulation, and the final verdict.

The latest issue · 001

BPC-157

The molecule most abused by Brazilian marketing.

Scroll to reveal
◯ Issue 001 · In preparationNext Thursday

The closed sphere of peptides, biohacking and transformation protocols.

Every Thursday, one molecule. Decoded with the precision of someone who read the original paper and the clarity of someone with nothing to sell. Mechanism, real evidence, regulatory status — and the final verdict.

Most of what's published about peptides in Brazil is an influencer selling an affiliate link.

Every issue cites the paper.

If a protocol appears in PeptoSfera, it's anchored in peer-reviewed literature. We cite the author, the year, the sample size. You read the sentence and know exactly where it came from.

We never sell what we recommend.

PeptoSfera has no affiliate links, no commission program, and resells no vials. The subscription is the only source of revenue — and that's what keeps the verdict honest.

Every issue ends with worth running or not.

No "it depends on your case, talk to your doctor." The literature allows an answer — and PeptoSfera picks a side. Yes, conditional, or no. You pay for the position, not the asterisk.

One molecule. Every Thursday. Decoded.

BPC-157: what the science supports and what marketing invented.

In July the US opened the door and Brazil closed its own. What the evidence actually shows, why almost all of it is animal — and the final verdict.

TB-500: BPC-157's systemic sibling and the synergy nobody proved.

Why it appeared in the same ANVISA statement and the same FDA vote. Mechanism, what the literature supports about the combination — and the final verdict.

Tirzepatide vs. Semaglutide: what separates the two molecules that redefined aesthetics.

The only two in this sphere with registration and prescription in Brazil. Mechanism, side-effect profile, what the label authorises — and the case where Semaglutide still wins.

The closed sphere exists. Most people just weren't invited.

“Most of what's published about peptides in Brazil is an influencer selling an affiliate link. PeptoSfera was born to be the opposite: someone who reads the papers in English, talks to São Paulo's sports physicians, and tells you — in plain language — what's worth running and what's marketing. No broscience. No affiliates. Just science, decoded every Thursday.”
The Editor · PeptoSfera · Letter to the first subscribers

Three levels. One criterion: how seriously you take this.

Starter
R$29 / mo
For those beginning to observe.
  • Full weekly issue
  • Last 30 days archive
  • Email every Thursday at 06:00
Subscribe now
Sphere
R$79 / mo
For those building.
  • Everything in Insider
  • Private WhatsApp (100 seats)
  • Monthly live Q&A with the editor
  • 48h early access
Subscribe now
Reserve your place in the sphere

Issue 001 ships Thursday, 06:00 BRT.